Hospital
Community Health Network, INC
Community Health Network, INC was paid $161.73M by Medicaid between Jan 2018 and Dec 2024, across 210 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoCOMMUNITY HEALTH NETWORK, INC
INDIANAPOLIS, IN 46219
INDIANAPOLIS, IN 46219
33aNPI1336119478assigned 01/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$161.73M
24GClaims2,522,106
24DCodes billed210
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#1 of 69
Median peer was paid$9.76M
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 320,616 | $8.74M | |
| 2019 | 319,064 | $17.29M | |
| 2020 | 280,028 | $19.67M | |
| 2021 | 394,594 | $29.62M | |
| 2022 | 509,554 | $33.04M | |
| 2023 | 405,485 | $30.92M | |
| 2024incomplete | 292,765 | $22.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 198,739 | 166,800 | $29.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 120,049 | 105,972 | $18.09M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 8.7% | 122,567 | 75,964 | $14.03M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.2% | 171,678 | 99,978 | $11.70M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.7% | 12,159 | 4,258 | $7.53M |
| 71045 | Radiologic examination, chest; single view | 4.4% | 49,995 | 41,586 | $7.17M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.2% | 107,253 | 82,882 | $6.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 43,924 | 35,757 | $5.96M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.0% | 33,828 | 14,179 | $4.92M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 12,763 | 10,289 | $4.85M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 91,779 | 74,487 | $3.97M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.4% | 35,865 | 32,662 | $3.88M |
198 more codes
| J9271 | Injection, pembrolizumab, 1 mg | 2.3% | 664 | $3.77M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 2.2% | 70,656 | $3.53M |
| 99214 | Doctor's office visit, returning patient (more involved) | 2.0% | 24,610 | $3.16M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 54,725 | $2.18M |
| 90832 | Psychotherapy session, about 30 minutes | 1.2% | 15,922 | $1.99M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 26,019 | $1.97M |
| Q3014 | Telehealth originating site facility fee | 1.1% | 34,092 | $1.76M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 20,045 | $1.73M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 14,101 | $1.62M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13,524 | $1.48M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,300 | $1.29M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,001 | $1.15M |
| 36591 | <1% | 21,034 | $1.07M | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 231,379 | $958K |
| 90837 | Psychotherapy session, about an hour | <1% | 7,403 | $916K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 58,897 | $884K |
| 90839 | <1% | 7,260 | $826K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,365 | $804K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,166 | $783K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 9,242 | $687K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,534 | $645K |
| J0897 | Injection, denosumab, 1 mg | <1% | 546 | $638K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,565 | $589K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 771 | $577K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 107,491 | $516K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,073 | $479K |
| 84484 | <1% | 68,339 | $472K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 8,048 | $467K |
| 80053 | Comprehensive metabolic panel | <1% | 77,459 | $387K |
| 36415 | Collection of venous blood by venipuncture | <1% | 156,233 | $372K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,187 | $335K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 3,099 | $316K |
| 96417 | <1% | 3,023 | $304K | |
| 81025 | <1% | 53,194 | $293K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,039 | $271K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,837 | $255K |
| 77336 | <1% | 1,539 | $206K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,218 | $175K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,199 | $164K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,478 | $160K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 32,398 | $151K |
| 83690 | <1% | 37,799 | $130K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,231 | $128K |
| 99217 | <1% | 363 | $119K | |
| 77386 | <1% | 134 | $118K | |
| 99218 | <1% | 334 | $108K | |
| 81001 | <1% | 54,514 | $106K | |
| 99221 | <1% | 273 | $103K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,591 | $101K |
| 80076 | <1% | 19,823 | $100K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 773 | $99K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,600 | $95K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 319 | $95K |
| 87088 | <1% | 19,291 | $90K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 767 | $85K |
| 97161 | <1% | 793 | $80K | |
| 80047 | <1% | 17,108 | $72K | |
| 82728 | <1% | 9,691 | $72K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 47 | $68K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 325 | $67K |
| 80050 | General health panel | <1% | 368 | $63K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,666 | $59K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 247 | $55K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 91 | $53K |
| 77412 | <1% | 172 | $50K | |
| 77334 | <1% | 221 | $44K | |
| 83550 | <1% | 8,901 | $43K | |
| G0378 | Hospital observation service, per hour | <1% | 730 | $39K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 31,850 | $38K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 206 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,994 | $35K |
| 83540 | <1% | 8,926 | $32K | |
| 83880 | <1% | 1,624 | $32K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 604 | $32K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 499 | $31K |
| 93017 | <1% | 208 | $30K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 28 | $28K |
| 76642 | <1% | 212 | $25K | |
| 96415 | <1% | 368 | $24K | |
| 95811 | <1% | 14 | $23K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 96 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,037 | $22K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 988 | $21K |
| 87634 | <1% | 308 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,718 | $14K |
| 77300 | <1% | 77 | $13K | |
| 84439 | <1% | 3,385 | $13K | |
| 36592 | <1% | 615 | $12K | |
| 72170 | <1% | 447 | $12K | |
| 82607 | <1% | 1,382 | $11K | |
| 83520 | <1% | 780 | $11K | |
| 82746 | <1% | 1,253 | $10K | |
| 86334 | <1% | 1,156 | $9K | |
| 82784 | <1% | 856 | $9K | |
| 96416 | <1% | 48 | $9K | |
| 85014 | <1% | 6,930 | $9K | |
| 73564 | <1% | 241 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 709 | $7K |
| 99234 | <1% | 16 | $7K | |
| 97597 | <1% | 93 | $7K | |
| 20610 | <1% | 73 | $7K | |
| 82553 | <1% | 4,405 | $7K | |
| 72100 | <1% | 163 | $7K | |
| 96402 | <1% | 795 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 151 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 45 | $6K |
| 83735 | <1% | 1,737 | $5K | |
| 80305 | <1% | 467 | $5K | |
| 11045 | <1% | 29 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 567 | $5K |
| 85379 | <1% | 648 | $4K | |
| 96367 | <1% | 251 | $4K | |
| 84165 | <1% | 1,806 | $4K | |
| 74018 | <1% | 36 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 23 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 765 | $3K |
| 81003 | <1% | 2,519 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $3K |
| 71250 | <1% | 14 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $3K |
| 94799 | <1% | 185 | $3K | |
| 85027 | <1% | 809 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $2K |
| 84100 | <1% | 1,402 | $2K | |
| 83883 | <1% | 246 | $2K | |
| 87081 | <1% | 453 | $2K | |
| 87808 | <1% | 197 | $2K | |
| 82565 | <1% | 567 | $2K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 78 | $2K |
| 96376 | <1% | 697 | $2K | |
| 29581 | <1% | 21 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 30 | $1K |
| 94760 | <1% | 44 | $1K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 281 | $1K |
| 83521 | <1% | 108 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 157 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 29 | $891.40 |
| 82947 | <1% | 161 | $776.60 | |
| 94060 | <1% | 13 | $765.32 | |
| 73562 | <1% | 20 | $747.58 | |
| 87905 | <1% | 80 | $745.43 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $594.00 |
| 82657 | <1% | 62 | $560.08 | |
| 83921 | <1% | 78 | $555.16 | |
| 82077 | <1% | 45 | $536.00 | |
| 87077 | <1% | 110 | $531.52 | |
| 82962 | <1% | 241 | $497.83 | |
| 73610 | <1% | 19 | $478.03 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 232 | $476.28 |
| 82378 | <1% | 52 | $448.41 | |
| 94761 | <1% | 37 | $392.80 | |
| 87641 | <1% | 12 | $315.81 | |
| 94726 | <1% | 13 | $283.68 | |
| 83605 | <1% | 36 | $254.28 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $244.89 |
| 83090 | <1% | 23 | $207.88 | |
| 84132 | <1% | 65 | $190.96 | |
| 80306 | <1% | 29 | $185.30 | |
| 81002 | <1% | 148 | $176.26 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,586 | $174.20 |
| 85610 | <1% | 49 | $154.39 | |
| 84295 | <1% | 51 | $141.08 | |
| 85018 | <1% | 158 | $127.61 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,732 | $123.86 |
| 84155 | <1% | 101 | $113.10 | |
| 82948 | <1% | 46 | $84.98 | |
| 84702 | <1% | 12 | $83.56 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,727 | $83.17 |
| 82435 | <1% | 30 | $81.12 | |
| 87186 | <1% | 16 | $75.59 | |
| 84520 | <1% | 30 | $69.66 | |
| 73130 | <1% | 46 | $45.93 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 75 | $37.28 |
| 83615 | <1% | 12 | $26.04 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $25.81 |
| 85378 | <1% | 15 | $18.84 | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 74 | $4.97 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,139 | $2.40 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 292 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 102 | $0.00 |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 0% | 132 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 30 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 302 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 50 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 120 | $0.00 |
| 72110 | 0% | 17 | $0.00 | |
| 77387 | 0% | 164 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 36 | $0.00 |
| 94729 | 0% | 13 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 13 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 274 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 43 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 44 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 14 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLARD, HOLLY (SVP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Community Health Network, INC | Indianapolis, IN | $32.97M |
| Community Hospital of Anderson & Madison County, INC | Anderson, IN | $32.30M |
| Community Hospital South, INC. | Indianapolis, IN | $27.35M |
| Fairbanks Hospital, INC. | Indianapolis, IN | $18.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.